Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

被引：0
|
作者：
Modar Khalil
Hassan W Zafar
Victoria Quarshie
Fayyaz Ahmed
机构：
[1] Hull Royal Infirmary,Specialist Registrar in Neurology
[2] Hull Royal Infirmary,Specialist Headache Nurse
[3] Consultant Neurologist,undefined
[4] Hull Royal Infirmary,undefined
来源：
The Journal of Headache and Pain | 2014年 / 15卷
关键词：
Migraine; National Health Service; Chronic Migraine; Medication Overuse; Episodic Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
    HC Diener
    DW Dodick
    RE DeGryse
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
  • [42] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey Manack
    FRONTIERS IN NEUROLOGY, 2022, 12
  • [43] Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients
    Santoro, Antonio
    Tanzi, Matteo
    Miscio, Anna
    Copetti, Massimiliano
    Leone, Maurizio
    JOURNAL OF HEADACHE AND PAIN, 2015, 16
  • [44] Early outcomes of migraine after erenumab discontinuation: data from a real-life setting
    De Matteis, Eleonora
    Affaitati, Giannapia
    Frattale, Ilaria
    Caponnetto, Valeria
    Pistoia, Francesca
    Giamberardino, Maria Adele
    Sacco, Simona
    Ornello, Raffaele
    NEUROLOGICAL SCIENCES, 2021, 42 (08) : 3297 - 3303
  • [45] Early outcomes of migraine after erenumab discontinuation: data from a real-life setting
    Eleonora De Matteis
    Giannapia Affaitati
    Ilaria Frattale
    Valeria Caponnetto
    Francesca Pistoia
    Maria Adele Giamberardino
    Simona Sacco
    Raffaele Ornello
    Neurological Sciences, 2021, 42 : 3297 - 3303
  • [46] Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine's Prophylaxis
    Maraia, Zaira
    Ricci, Diletta
    Rocchi, Marco Bruno Luigi
    Moretti, Alessandro
    Bufarini, Celestino
    Cavaliere, Arturo
    Peverini, Manola
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [47] Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
    Corbelli, Ilenia
    Verzina, Angela
    De Magistris, Ilaria Leone
    De Vanna, Gioacchino
    Eusebi, Paolo
    Mataluni, Giorgia
    Pisani, Antonio
    Prudenzano, Addolorata Maria Pia
    Trojano, Maria
    Delussi, Marianna
    De Tommaso, Marina
    Russo, Antonio
    Silvestro, Marcello
    Tedeschi, Gioacchino
    Calabresi, Paolo
    Sarchielli, Paola
    TOXINS, 2023, 15 (01)
  • [48] Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
    Kaname Ueda
    Wenyu Ye
    Louise Lombard
    Atsushi Kuga
    Yongin Kim
    Sarah Cotton
    James Jackson
    Tamas Treuer
    The Journal of Headache and Pain, 2019, 20
  • [49] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Dikmen, Pinar Yalinay
    Kosak, Seda
    Aydinlar, Elif Ilgaz
    Kocaman, Ayse Sagduyu
    ACTA NEUROLOGICA BELGICA, 2018, 118 (03) : 475 - 484
  • [50] Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
    Ueda, Kaname
    Ye, Wenyu
    Lombard, Louise
    Kuga, Atsushi
    Kim, Yongin
    Cotton, Sarah
    Jackson, James
    Treuer, Tamas
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1)
12345